Recruiting PHASE2 INTERVENTIONAL 7-arm NCT05061550

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Sponsor: AstraZeneca

Conditions Non-small Cell Lung Cancer

Interventions AZD0171 Carboplatin Carboplatin/Paclitaxel Cisplatin Dato-DXd Durvalumab Monalizumab Oleclumab Pemetrexed/Carboplatin Pemetrexed/Cisplatin Rilvegostomig Volrustomig

Updated 42 times since 2021 Last updated: Mar 9, 2026 Started: Apr 14, 2022 Primary completion: May 28, 2030 Completion: May 28, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by AstraZeneca and has accumulated 42 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

42 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE2
Jan 2026 — Mar 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2

▶ Show 37 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE2
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
May 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Jan 2023 — Mar 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE2
Oct 2021 — Dec 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Parexel

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Alicante, Spain , Ankara, Turkey (Türkiye) , Aviano, Italy , Avignon, France , Baltimore, United States , Barcelona, Spain , Bobigny, France , Bordeaux, France , Boston, United States and 70 more locations